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Sympathetic Nervous System
Activation in Human Heart Failure
Clinical Implications of an Updated Model
John S. Floras, MD, DPHIL
Toronto, Ontario, Canada
Disturbances in cardiovascular neural regulation, influencing both disease course and survival, progress as heart
failure worsens. Heart failure due to left ventricular systolic dysfunction has long been considered a state of gen-
eralized sympathetic activation, itself a reflex response to alterations in cardiac and peripheral hemodynamics
that is initially appropriate, but ultimately pathological. Because arterial baroreceptor reflex vagal control of
heart rate is impaired early in heart failure, a parallel reduction in its reflex buffering of sympathetic outflow has
been assumed. However, it is now recognized that: 1) the time course and magnitude of sympathetic activation
are target organ–specific, not generalized, and independent of ventricular systolic function; and 2) human heart
failure is characterized by rapidly responsive arterial baroreflex regulation of muscle sympathetic nerve activity
(MSNA), attenuated cardiopulmonary reflex modulation of MSNA, a cardiac sympathoexcitatory reflex related to
increased cardiopulmonary filling pressure, and by individual variation in nonbaroreflex-mediated sympathoexcit-
atory mechanisms, including coexisting sleep apnea, myocardial ischemia, obesity, and reflexes from exercising
muscle. Thus, sympathetic activation in the setting of impaired systolic function reflects the net balance and
interaction between appropriate reflex compensatory responses to impaired systolic function and excitatory
stimuli that elicit adrenergic responses in excess of homeostatic requirements. Recent observations have been
incorporated into an updated model of cardiovascular neural regulation in chronic heart failure due to ventricular
systolic dysfunction, with implications for the clinical evaluation of patients, application of current treatment,
and development of new therapies. (J Am Coll Cardiol 2009;54:375–85) © 2009 by the American College of
Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.03.061n
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eart failure (HF) has implications for both disease progres-
ion and survival (1,2). The prevailing model, as illustrated
n the Journal in 1993 (3), assumes that this begins when left
entricular systolic dysfunction elicits reflexively a general-
zed increase in sympathetic outflow directed at all vascular
eds. Its subsequent augmentation plus concurrent diminu-
ion of reflex vagal heart rate (HR) modulation are attrib-
ted primarily to dysfunction of 2 sets of sympathoinhibi-
ory reflexes engaged by stimulation of mechanoreceptor
fferents: 1) arterial baroreceptors, which stretch less as
ystolic and pulse pressures diminish; and 2) cardiopulmo-
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009, accepted March 23, 2009.ary baroreceptor reflexes, which may be damaged by prior
yocardial infarction, stimulated less as inotropy dimin-
shes, or altered by ventricular dilation (3).
However, recent investigations have identified afferent,
entral neural, and efferent sympathoexcitatory mechanisms
ot addressed by this model, plus a selective, rather than
eneralized, alteration in autonomic regulation early in HF,
ith attenuation of heart rate variability (HRV) (4) and a
elective elevation of cardiac norepinephrine spillover
CNES) (5) preceding rises in total body norepinephrine
pillover (TNES), renal norepinephrine spillover (RNES),
nd muscle sympathetic nerve activity (MSNA). Also, the
odel does not inform why MSNA burst frequency (or
R-corrected burst incidence) in many patients with pro-
ound ventricular systolic dysfunction is similar to that of
ge- or sex-matched healthy subjects (5,6). Often, sympa-
hetic excitation is present only when other clinical charac-
eristics such as impaired exercise capacity (6,7), sleep-
elated breathing disorders (Fig. 1) (8), or ischemic heart
isease (9) coexist. Importantly, at left ventricular ejection
ractions below 35%, this no longer correlates with nerve
ring rate (6–8,10). These observations, which argue
gainst ventricular systolic dysfunction per se as the princi-
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Sympathetic Excitation in Human HF July 28, 2009:375–85pal stimulus to sympathetic acti-
vation, have implications for the
clinical evaluation of patients,
application of current treatment,
and development of new therapies.
The purpose of this review is
2-fold: 1) to propose a contem-
porary model that integrates
newer knowledge concerning
mechanisms responsible for tem-
poral, regional, and interindi-
vidual heterogeneity of sympa-
thetic activation in human HF
due to left ventricular systolic
dysfunction; and 2) to discuss the
implications of this model for the
investigation and management of
the HF patient, and for future
clinical trial design and recruit-
ment. Several of these concepts
also might apply to patients with
HF, but relatively preserved sys-
tolic function, in whom the sym-
pathetic nervous system would
ot appear to be as active as in systolic dysfunction, and
RV not as depressed (11–14).
timuli to Sympathetic Activation and
ugmented Neural Norepinephrine (NE) Release
ur present understanding of the diversity of sympathoex-
itatory mechanisms engaged by HF arises primarily from
Abbreviations
and Acronyms
BP  blood pressure
CNES  cardiac
norepinephrine spillover
CPAP  continuous
positive airway pressure
CSA  central sleep apnea
HF  heart failure
HR  heart rate
HRV  heart rate variability
LBNP  lower body
negative pressure
MSNA  muscle
sympathetic nerve activity
NE  norepinephrine
OSA  obstructive sleep
apnea
RNES  renal
norepinephrine spillover
TNES  total body
norepinephrine spillover
Figure 1 Muscle Sympathetic Burst Incidence
at Rest in Subjects With and Without HF
Scattergrams and mean  standard error for muscle sympathetic nerve activity
(MSNA) (bursts/100 cardiac cycles) in treated heart failure (HF) patients with
(SD) and without sleep-disordered breathing (NSD) (8), compared with age-
matched healthy laboratory control subjects. MSNA is increased significantly
when apnea coexists with HF (p  0.005), whereas MSNA in treated HF
patients without apnea is similar to MSNA in control subjects.The application of NE kinetic methodology (which quanti-
es total body, cardiac, renal, brain, or forearm NE spillover
nto plasma) (2,15,16) and from microneurographic record-
ngs obtained from sympathetic fibers innervating muscle or
utaneous vascular beds (17,18). By contrast, HRV reflects
he fidelity with which post-junctional sinoatrial receptors
espond to oscillations in sympathetic and vagal nerve
ischarge, rather than the absolute magnitude of neuro-
ransmitter released (19). Mechanical stretch of the sino-
trial node, for example by high right atrial pressure, will
lso decrease HRV (20). In conscious paced sheep, directly
ecorded cardiac sympathetic nerve firing rate increases
arkedly as HF develops, without affecting low-frequency
R spectral power (21). Consequently, in human HF,
RV analysis provides neither direct nor definitive mech-
nistic information concerning cardiac autonomic regulation.
fferent Mechanisms
rterial baroreceptor reflexes. Arterial baroreflex-mediated
R responses to drug-induced blood pressure (BP) changes
re clearly diminished in human HF (22–24). Such impair-
ent also foreshortens survival (25). However, efferent vagal
nd sympathetic responses to arterial baroreceptor stimula-
ion are not invariably concordant: with both healthy aging
26) and primary hypertension (27) arterial baroreflex reg-
lation of HR is attenuated, yet reflex modulation of
SNA is preserved. In an ovine model of pacing-induced
F in which cardiac sympathetic nerve activity (CSNA)
as recorded directly, burst frequency was increased, and
he baroreceptor regulation of HR profoundly impaired,
ikely as a result of both altered pre-synaptic vagal gangli-
nic neurotransmission (28) and blunted sinoatrial respon-
iveness to the neurotransmitter NE (29), whereas the reflex
ontrol of CSNA did not differ from normal sheep (21).
In the paced-canine model, electrical stimulation of the
arotid sinus nerve to increase baroreceptor afferent input
licits a significant fall in plasma NE concentration (30), yet
inoaortic baroreceptor denervation has no effect on the
ime course of changes in hemodynamics and plasma NE
oncentrations as HF develops (31). Therefore, in this
reparation, the set point for sympathetic vasoconstrictor
one is increased centrally, rather than as a consequence of
iminished baroreceptor stimulation, resetting, or reflex
ain; the functional sympathomodulatory capacity of this
eflex is preserved.
In chronic human HF, the presence of a significant
nverse relationship between stroke work index and MSNA
32) suggests that the arterial baroreflex retains the capacity
o modify efferent sympathetic outflow about a higher set
oint in response to changes in cardiac output or BP.
ttenuation of efferent MSNA responses to pharmacolog-
cal baroreceptor perturbation has not been observed con-
istently (22,33,34), but there are several limitations to the
nterpretation of sympathetic responses to vasoactive drugs.
hese infusions will alter cardiac loading conditions, with
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July 28, 2009:375–85 Sympathetic Excitation in Human HFnpredictable effects on low-pressure mechanoreceptor
erve firing. Induced BP changes are of relatively slow
nset, whereas arterial baroreceptors transduce best high-
requency oscillations (35). Nitric oxide donors such as
itroprusside may inhibit directly sympathetic neurotrans-
ission (36). Importantly, because HR responses to these
nduced changes in BP are attenuated, the potential magnitude
f concurrent variations in HR-dependent variables, such as
ympathetic burst frequency, will be constrained as a direct
onsequence. Conversely, if MSNA responses expressed as
bsolute or relative increase in discharge frequency (bursts/min)
23) are recalculated as HR-independent variables (e.g., change
n bursts/100 cardiac cycles), values for arterial-MSNA barore-
ex gain do not differ appreciably between HF and healthy
ontrol subjects (18).
Independent, but complementary, methods provide ad-
itional evidence that arterial baroreflex control of sympa-
hetic nerve activity is relatively intact in HF. Key observa-
ions include: 1) preserved MSNA pulse-synchronicity (37);
) immediate reflex augmentation of MSNA burst ampli-
ude and duration in response to the long diastolic period
ollowing a ventricular ectopic complex (18,38), with sub-
equent post-extrasystolic suppression of MSNA propor-
ional to the diastolic pressure overshoot (39); 3) MSNA
racks reflexively pulsus alternans (37); 4) reflex reductions
n MSNA when diastolic pressure rises modestly upon left
r biventricular pacing (40); 5) similar inhibition of MSNA
y aortic and ventricular mechanoreceptor stimulation in
ubjects with normal and impaired ventricular systolic func-
ion (41); 6) similar reflex increases in TNES in patients and
ontrol subjects with nitroprusside infusion to achieve com-
arable baroreceptor unloading (42); and 7) similar gain, in
ubjects with and without HF, of the cross-spectral transfer
unction between BP (stimulus) and MSNA (response)
cross all frequency bands (35).
By contrast, renal studies evaluating responses to hypo-
ension induced by nitroprusside revealed an 85% increase in
NES in healthy controls, but no net change in HF, albeit
rom a nearly 3-fold higher baseline (16). What is uncertain
s whether this finding represents a ceiling effect (i.e., RNES
annot increase further, as suggested by ovine renal sympa-
hetic nerve data [43]), or the integrated response to
ombined arterial and cardiopulmonary receptor unloading.
n another study, low-dose nitroglycerin reduced pulmonary
ressures selectively without altering RNES in either HF or
ealthy subjects, whereas a higher hypotensive dose elicited
significant reduction only in those with systolic dysfunc-
ion (44).
ardiopulmonary reflexes. Cardiopulmonary baroreceptor
eflexes elicit sympathoinhibition when stimulated by in-
reased filling pressures, chamber volume, or inotropy, and
ympathoexcitation when unloaded, for example, by lower
ody negative pressure (LBNP). Dunlap et al. (33), who
nfused phenylephrine at the peak depressor response to
itroprusside, observed similar gains in the arterial barore-
ex control of MSNA in healthy and HF subjects, whereas (eflex responses to stimuli that raised and lowered cardiac
lling pressure without affecting systemic pressure were
ttenuated. These investigators concluded that the funda-
ental regulatory defect in human HF was impairment of
ardiopulmonary (not arterial) baroreflex-mediated inhibi-
ion of sympathetic discharge (33,34).
However, increased cardiac filling pressure appears to
timulate in addition an ordinarily quiescent “low-pressure”
xcitatory reflex, arising from myelinated cardiac vagal
45,46) and/or cardiac sympathetic afferent nerves (47), that
xcites specifically cardiac adrenergic discharge. In normal
ogs, a cardiac sympathetic afferent reflex can be potentiated
y acute volume expansion (48,49), and in a pacing-induced
anine HF model, Zucker’s group has demonstrated also
ensitization of cardiac sympathetic afferents responsive to
hemical stimuli, and amplification of the central gain of the
ardiac sympathetic afferent reflex through an angiotensin
I–mediated mechanism (48,50). Several observations in
uman HF are consistent with this concept: 1) the selective
ncrease in cardiac norepinephrine spillover (CNES) in mild
F (5); 2) forearm vasoconstriction in response to saline
nfusion in mild HF, but not in control subjects (51); 3)
ignificant positive relationships between left ventricular
lling pressures or pulmonary artery pressures, on the one
and, and either CNES or MSNA (15,32); 4) attenuation,
n patients with impaired systolic function, of the reflex
ncrease in CNES elicted by a hypotensive infusion of
itroprusside (42); 5) paradoxical reductions in CNES when
itroprusside lowered both atrial and arterial pressure of
atients with severe secondary pulmonary hypertension
52); 6) in HF patients, a paradoxical fall in CNES (but no
hange in TNES) when atrial and ventricular transmural
ressure were reduced acutely by continuous positive airway
ressure (CPAP) (53), or when atrial pressure was reduced
electively by nonhypotensive LBNP (54); and 7) absence of
ny significant reflex increase in CNES (present when
entricular systolic function is normal) in response to
ypotensive LBNP (54).
ulmonary reflexes. The classical model (3) discounts the
ntrainment of MSNA by breathing in HF. Although this
s preserved (35,55), neural silence with inspiration requires
igher tidal volumes than in healthy subjects (55). Patients
ith low tidal volume and high respiratory frequency exhibit
high burst incidence (56). Brief periods of apnea elicit
arked increases in MSNA (38). Rapidly adapting vagal
ensory receptors located in the airways respond to lung
nflation and deflation, and also to increases in left atrial
ressure and extravascular pulmonary fluid volume (57).
eripheral chemoreceptor reflexes. The contribution of
rterial chemoreceptors to sympathetic activation in experi-
ental HF models has been reviewed in detail (58). In
ealthy humans, brief exposure to hypoxia elicits sustained
ncreases in MSNA, persisting long after reoxygenation
59). Augmented peripheral chemoreceptor sensitivity to
ypoxia, present in perhaps 40% of treated HF patients
60,61), is associated with several autonomic disturbances
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Sympathetic Excitation in Human HF July 28, 2009:375–85ith prognostic implications. These include higher plasma
E, impaired arterial baroreflex control of HR, but loss of
RV, very low-frequency oscillations in breathing during
oth sleep and wakefulness, enhanced ventilatory responses
o exercise, and an increased propensity to nonsustained
entricular tachycardia (60–62).
Di Vanna et al. (63) reported increased MSNA responses
o hypoxic (peripheral) and hypercapneic (central) chemo-
eceptor stimulation in the New York Heart Association
NYHA) functional class II to III HF patients compared
ith controls. However, in 2 studies, inhalation of 100% O2
to suppress peripheral chemoreceptor input) had no effect
n mean MSNA values, suggesting that chemoreceptor-
ediated sympathoexcitation may not be as prevalent in the
roader HF population (64,65). These experiments were
onducted in resting subjects; this mechanism is augmented
y exercise (66).
leep-related breathing disorders. During nonrapid eye
ovement sleep, MSNA, BP, and HR normally fall
67,68), whereas vagal activity and the arterial baroreflex
ontrol of HR increase (69,70). The briefer and interrupted
leep characteristic of systolic dysfunction (71) increases the
ntegrated (24 h) adrenergic burden upon the failing heart
nd circulation.
Sleep-related breathing disorders, potent stimuli to
cute and sustained sympathoexcitation, are also absent
rom the current model (3), yet sleep apnea is present in
he majority of symptomatic patients. Approximately
ne-third exhibit obstructive sleep apnea (OSA), and
ne-third central sleep apnea (CSA) (72,73). By deacti-
ating pulmonary stretch receptors and stimulating pe-
ipheral and central chemoreceptors by hypoxia and
ypercapnia, each pause in breathing during sleep elicits
rofound increases in MSNA (74). This sympathetic
xcitation is independent of and in addition to any reflex
esponses to mechanoreceptor unloading resulting from
ump failure or systemic hypotension. Inspiratory efforts
gainst a collapsed upper airway, as occurs in OSA will
enerate extreme negative swings in intrathoracic pres-
ure (i.e., an abrupt increase in left ventricular afterload).
ecause the failing heart is more sensitive to increases in
fterload, obstruction provokes an acute fall in stroke
olume and diastolic BP (75). This unloading of arterial
aroreceptors elicits a reflex increase in MSNA of greater
ntensity in HF than in subjects with normal venticular
unction, who are better able to maintain stable systemic
P in the face of this mechanical stimulus (41). Arousal,
hich terminates an apneic event, is accompanied by a
urther rise in central sympathetic outflow and BP plus
agal withdrawal (74,76). These cycles of apnea and
rousal expose the failing heart and peripheral circulation
ach night to repetitive surges of central sympathetic
utflow and NE release far greater than required for
irculatory homeostasis.
Sympathoexcitation carries over into wakefulness (8,74).
rassi et al. (77) identified higher daytime MSNA in HF batients with obesity or hypertension, but did not report the
revalence of sleep apnea in these high-risk populations
72,78). Compared with HF patients without sleep apnea,
n those with coexisting OSA, MSNA was 11 bursts/100
eart beats higher (Fig. 1); in a subset studied in a
andomized controlled trial, MSNA fell by 12 bursts/100
eart beats after OSA was abolished (8,79). These data
rovide important evidence in human HF for convergence,
n central sympathetic neurons, of input from 2 indepen-
ent sympathoexcitatory influences that increase MSNA
hrough a process of additive summation (80) (Fig. 2). This
dditional OSA-mediated sympathoexcitation could accel-
rate HF mortality rates (73).
Compared with HF patients otherwise matched, but
ithout sleep-related breathing disorders, those with CSA
ave greater nocturnal urinary NE excretion and plasma NE
oncentrations while awake (81). MSNA during wakeful-
ess is also increased (8). Mansfield et al. (82) attributed
igher rates of CNES and TNES in HF patients with CSA
o greater hemodynamic decompensation, but because sub-
ects were dichotomized using a very low apnea–hypopnea
ndex (5 events/h vs. 15 events/h), a direct comparison
ith microneurographic findings is uninformative.
yocardial ischemia and infarction. Myocardial isch-
mia and prior infarction have the potential to exert an
cute or chronic effect on sympathetic outflow that is
oth additive to and independent of the magnitude of
ystolic dysfunction (83,84). If cardiac output, and hence
P, fell as a consequence of ischemia, unloading of
inoaortic baroreceptors should elicit a further reflexive
ncrease. When studied 6 months after myocardial in-
arction, patients with relatively preserved ejection frac-
ion (mean 52%) had higher MSNA burst incidence than
oronary artery disease patients or healthy control sub-
ects (85). Ischemic patients exhibit higher plasma NE
oncentrations than dilated cardiomyopathy patients (86).
rassi et al. (87) reported virtually identical values for MSNA
n these 2 populations; in a comparison involving younger
atients (by 5 to 10 years) with lower mean ejection fractions
22% vs. 33%), MSNA was significantly higher in those with
schemic cardiomyopathy (9).
eflexes arising from skeletal muscle. Several neural
echanisms, arising from skeletal muscle, have the capacity
o increase the set point for central sympathetic outflow in
F at rest or during exercise. These include: 1) a sympa-
hoexcitatory reflex, stimulated by adenosine, with the
articipation of angiotensin acting via the AT1 receptor as a
eural intermediary (88,89); 2) increases in local venous
ressure (90); 3) activation, in HF, of a muscle mechanore-
ex (91) elicited by passive exercise; and 4) a muscle
etaboreflex elicited by both isotonic and isometric hand-
rip (6,89). The latter is activated at a lower workload in HF
han in age-matched healthy control subjects, and intensi-
es in those in whom predicted exercise VO2 peak falls
elow 56% (6). An important consequence is that values for
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July 28, 2009:375–85 Sympathetic Excitation in Human HFlasma NE acquired at rest do not predict the magnitude of
ympathetic activation during exercise.
xcitatory reflexes arising from the kidney. In patients
ith chronic renal failure, an afferent signal from the uremic
idney stimulates MSNA (92). This reflex may become
unctionally important in patients with renal insufficiency or
ight HF.
entral Integration and Interactions
he initial concept that the central nervous system simply
ntegrates information from these several afferent inputs,
nd then transmits output passively, has been superseded by
vidence demonstrating its active contribution to the auto-
omic disturbances of HF (93). In experimental HF mod-
ls, Zucker’s group has documented central augmentation of
ardiac sympathetic afferent reflex regulation of renal sym-
athetic nerve activity, arising from increases in central
ngiotensin II and in rostral ventral lateral medulla (VLM)
ngiotensin AT1 receptor and NAD(P)H oxidase subunit
ene expression, with consequent generation of reactive
xygen species, plus a decrease in local synthesis of neuronal
itric oxide (which exerts sympathoinhibitory actions at
Figure 2 Summation and Interaction of Reflexes Causing Direc
Convergence of afferent input from 2 sets of reflexes (e.g., HF and sleep apnea) e
trally through mutual inhibition, addition, or mutual facilitation. The difference in M
sleep apnea (OSA) (8) is eliminated when OSA is abolished (79). Thus, these 2 st
(80). Abbreviations as in Figure 1.everal brain sites) (94,95). The hypotheses proposed by rhese investigators are: 1) the set point for sympathetic
utflow is elevated as a consequence of central enhancement
f cardiac reflex gain, rather than loss of arterial barorecep-
or input (31,96); and 2) increased central angiotensin II
nitiates this positive feedback loop by generating reactive
xygen species that alter neuronal excitability by modulating
on channel function (95).
Sympathetically mediated increases in renal renin release
ould amplify such positive feedback by increasing plasma
ngiotensin II, which interacts with the arterial baroreflex at
everal sites within and without the blood–brain barrier to
nhibit vagal discharge and increase central sympathetic out-
ow (97–99). In dogs without HF, peripheral infusion of
ngiotensin II attenuates the the hypotensive response to
hronic carotid baroreceptor stimulation (100); its chronic
entral infusion potentiates the cardiac sympathetic afferent
eflex (101).
Aldosterone of adrenal origin has been reported to
timulate the brain renin-angiotensin system by increasing
araventricular (hypothalamic) nucleus angiotensin AT1
eceptor mRNA, protein, and NAD(P)H oxidase subunit
ene expression and plasma NE concentrations (102). In
lly Similar Responses
directionally similar excitatory effects on MSNA may summate and interact cen-
ecorded during wakefulness between HF patients with and without obstructive
ppear to interact by summation. Adapted from Figure 2 in Abboud and Thamestiona
liciting
SNA r
imuli aats with experimental HF, intracerebroventricular infusion
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Sympathetic Excitation in Human HF July 28, 2009:375–85f spironolactone reduced renal sympathetic nerve firing and
ugmented its arterial baroreflex regulation (103). A re-
ently described central cytokine-mediated sympathoexcit-
tory pathway can also be attenuated by mineralocorticoid
eceptor blockade (104).
In human HF, Esler’s group has demonstrated significant
ncreases in internal jugular venous spillover of metabolites
f NE and epinephrine (15,105), with a positive correlation
etween brain NE turnover and cardiac NE spillover (105).
ggarwal et al. (106) detected 4-fold higher suprabulbar
ubcortical turnover of NE and a tendency to lower cortical
E turnover in treated patients, compared with control
ubjects, and a significant correlation between subcortical
E turnover and TNES in HF. These authors propose that
ctivation of noradrenergic neurons projecting rostrally from
he brain stem mediates this sympathetic excitation. Could
hronic sleep disruption exacerbate this centrally mediated
ncrease in adrenergic drive?
In a recent report, 47% of 60 consecutive patients with
reated NYHA functional class I to III HF exhibited
ncreased CO2 sensitivity (61). HF progression augments
entilatory and sympathetic neural responses to central
hemoreceptor stimulation by hypercapnia (61,63,107,108).
ithin-breath sympathoinhibition is attenuated (108). An
ncrease in the gain of the central chemoreflex response to
O2 could perpetuate the cyclical breathing oscillations
haracteristic of CSA (109); during apneas, sympathoexci-
ation is exaggerated (108). MSNA remains high after
aking (8,81).
fferent Mechanisms
n the hamster dilated cardiomyopathy model, early in-
reases in cardiac tyrosine hydroxylase and dopamine beta-
ydroxylase activity are followed by NE depletion and
estruction of sympathetic nerve terminals (110). In the
aced-rabbit model, ventricular systolic dysfunction and
ncreases in synaptic and plasma NE precede reversible
eductions in cardiac NE uptake and transporter density and
ubsequent reductions in myocardial beta-receptor density
111). In patients with NYHA functional class II to IV HF,
oth NE uptake-1 carrier density (112) and the fractional
ransmyocardial extraction of NE fall by 30% (5); conse-
uently NE spillover into the coronary sinus rises dispro-
ortionate to neuronal release (113). Abnormal cardiac NE
ptake can be improved with chronic beta-adrenoceptor
lockade (114).
Neural release of NE and acetylcholine may be modi-
ed by agents acting on pre-junctional receptors. Alpha2-
drenoceptor agonists, such as clonidine, inhibit NE
elease, with left ventricular (115), but not forearm,
lpha2-adrenoceptors (116) retaining this property in
uman HF. In experimental preparations, stimulation of
re-junctional AT1 receptors facilitates sympathetic gan-
lionic neurotransmission, and neural and adrenal cate-
holamine release (97), but it has proven difficult to
eplicate this action in humans (117). NE release and tdrenal catecholamine secretion also can be facilitated if
re-junctional beta2-adrenoceptors are stimulated by epi-
ephrine (118). Circulating activating antibodies against
eta1- and/or beta2-adrenoceptors, present in some patients
ith dilated cardiomyopathy, can mimic sympathoexcitatation
119). In a retrospective genetic-association study, Small et
l. (120) described a 6-fold greater risk of HF in
frican-American subjects homozygous for the hypo-
unctioning pre-junctional alpha2C Del322-325 polymor-
hism, and a 10-fold increase in those also homozygous
or the hyperfunctional post-junctional beta1 Arg329
eceptor, but provided no direct functional data concern-
ng cardiac NE release or post-junctional adrenergic
esponsiveness in this population. By contrast, in healthy
ubjects, variability in the NE response to the selective
lpha2-agonist dexmedetomidine was unaffected by ge-
otype (121), and in a cohort of patients with severe HF,
aye et al. (122) detected no relationship between the
lpha2C Del322-325 or beta2-adrenoceptor polymorph-
sm and cardiac NE release. The relationship between
E release and HR was steeper in beta2-adrenoceptor
rg 16 homozygotes, implying greater post-junctional
esponsiveness.
Muscarinic receptors on adrenergic nerve endings also
ttenuate NE release when stimulated by acetylcholine
123,124). Its intracoronary infusion in subjects with ven-
ricular systolic dysfunction decreased cardiac NE spillover,
n effect not seen in control subjects with normal left
entricular systolic function. Receptor blockade with atro-
ine had no effect in the HF group, but increased CNES in
ontrol subjects (125). Conversely, NE and Neuropeptide Y
eleased from sympathetic nerve endings inhibit acetylcho-
ine release by stimulating vagal pre-junctional receptors
126,127).
New Model
hus, sympathetic activation in the setting of impaired
ystolic function reflects the net balance and interaction
etween appropriate reflex compensatory responses to im-
aired systolic function and excitatory stimuli that elicit
drenergic responses in excess of homeostatic requirements,
ivoting upon a higher set point of central neural origin.
igure 3 integrates these concepts into a model in which:
) arterial baroreceptor reflex regulation of HR by the vagus
erve is impaired; 2) arterial baroreflex regulation of MSNA
s rapidly responsive to changes in diastolic BP, retains the
apacity to modulate generalized sympathetic discharge
42), and responds to the perception of diminished pulsatile
rterial mechanoreceptor stretch by adjusting, as required, a
entrally established set point for sympathetic outflow;
) pulmonary mechanoreceptor-mediated entrainment of
ympathetic outflow persists; 4) the conventional inhibitory
entricular baroreceptor reflex control of MSNA is blunted;
ut 5) elevated filling pressures can increase CNES early in
he course of HF by stimulating a cardiac-specific sympa-
hoexcitatory reflex.
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July 28, 2009:375–85 Sympathetic Excitation in Human HFThe time course and magnitude of hemodynamic
ompromise affecting these several baroreflex-mediated
echanisms could account for the considerable variation
etween patients with left ventricular systolic dysfunction
ith respect to the prevailing level of sympathetic activity
nd its organ-specific nature. If the progression to symp-
omatic HF is slow or if relatively normal stroke volume
nd BP can be maintained by increases in left ventricular
nd-diastolic volume, rather than cardiac filling pressure,
ncreasing ventricular mechanoreceptor firing could
aintain reflexively plasma NE concentrations, MSNA,
NES, and RNES within the normal range. Increasing
ardiac filling pressure to maintain stroke volume and
ystemic arterial pressure would have several conse-
uences: activation of the cardiac sympathetic reflex,
tself causing a reduction in arterial baroreflex vagal HR
Figure 3 Updated Model of Mechanisms Responsible for Sympa
As systolic dysfunction develops, inhibitory input from primarily ventricular mechan
the arterial baroreceptor and pulmonary stretch reflexes is preserved. Vagal modu
baroreflex perturbations are attenuated. Excitatory () inputs from an atrial reflex
tricular afferent nerve endings, triggered by ischemia, add to augmented sympatho
(thick lines). Renal afferent nerves (not shown) may also elicit sympathoexcitation
receptor-NADPH-superoxide axis, and sleep apnea. Potential efferent mechanisms
uptake. Early systolic dysfunction is characterized by a selective increase in cardia
advanced heart failure, there is a generalized increase in sympathetic nerve traffic
lation, and impairment of the reflex sympathetic regulation of vascular resistance.odulation (47), plus an atrial stretch-induced decrease dn high-frequency HRV (20). Afferent, central, and
anglionic (28) inhibition of parasympathetic tone would
ttenuate the restraining influence of acetylcholine on
ardiac NE release. Importantly, these are the first
bnormalities detected in human HF and those linked
ost closely to prognosis.
Chronically, increased cardiac NE release initiates sino-
trial beta1-adrenoceptor down-regulation and altered card-
ac beta-adrenoceptor signal transduction, destruction of
ympathetic terminals, and attenuation of NE reuptake
128). Should stroke volume alone not support systemic BP,
R will rise, through arterial baroreflex-mediated vagal
ithdrawal, and cardiac NE release will increase further; over
ime, arterial baroreceptor unloading by declining systemic
ressure will elicit generalized neurohumoral activation.
If the initial insult, such as an infarct, causes a sudden
ic Activation in Human Heart Failure
tors decreases (thin line), whereas efferent sympathetic nerve modulation by
f HR and efferent vagal and sympathetic heart rate (HR) responses to arterial
ted by increases in cardiac filling pressures, and from chemically sensitive ven-
tory input from arterial chemoreceptors and from exercising skeletal muscle
ral excitatory mechanisms (downward arrow) include an angiotensin II-AT1
e pre-/junctional facilitation of norepinephrine (NE) release and altered NE
elease and a reduction in tonic and reflex vagal HR modulation, whereas in
arrow shafts, thick lines), blunted vagal (thin line) and sympathetic HR modu-
acetylcholine; CNS  central nervous system; E  epinephrine.thet
orecep
lation o
activa
excita
. Cent
includ
c NE r
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Ach rop in cardiac output and BP, arterial baroreceptor unload-
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Sympathetic Excitation in Human HF July 28, 2009:375–85ng will immediately activate the sympathetic and renin-
ngiotensin systems and decrease vagal tone reflexively to
ompensate. Concurrent augmentation of afferent mech-
noreceptor or chemoreceptor nerve traffic, and peripheral
ngiotensin, aldosterone, or cytokines could activate central
ympathoexcitatory pathways (93). Pulmonary congestion,
ltered lung mechanics, and increased work of breathing will
ncrease further central sympathetic outflow (56).
Importantly, in a significant number of patients, addi-
ional nonbaroreflex-mediated excitatory stimuli, including
oexisting sleep apnea, myocardial ischemia, and obesity,
eflexes from exercising muscle, and/or alterations in central
ntegration or efferent autonomic regulatory systems may
upervene to elevate the set point for central sympathetic
utflow or neurotransmitter release at rest, during exercise,
r during sleep in excess of levels required to maintain
emodynamic stability, with important pathological conse-
uences. Inflammation may induce an additional nonneu-
onal source of catecholamines (129).
Contemporary diseased-based HF therapies such as beta-
drenoceptor antagonists, angiotensin-converting enzyme
nhibitors, angiotensin receptor antagonists, and digitalis
ounter, directly or indirectly, the adverse effects of excessive
ardiac and systemic sympathetic activity and augment vagal
one to improve symptoms, prognosis, or both. Beta-
drenoceptor antagonists address the earliest autonomic
isturbances identified in HF by countering the adverse
ffects of cardiac sympathetic overactivity, by augmenting
onic and reflex HR modulation (130,131), and by antago-
izing beta1-adrenergic–mediated stimulation of renin re-
ease, thereby lowering circulating concentrations of angio-
ensin II (132). In some, contemporary therapy appears
ufficient to restore sympathetic activity toward values ob-
ained in healthy control subjects, whereas in others, par-
icularly if nonbaroreflex stimuli to sympathetic nervous
ystem activation and increased NE release are not targeted,
igh sympathoadrenal activity may persist.
Figure 3 suggests several strategies, acting upon afferent,
entral, or efferent components of these baroreceptor- and
onbaroreceptor-mediated mechansisms that might be
ested in the future. Data from several small trials suggest
hat relief of congestion by diuresis-diminishing plasma NE
133) could also reduce the risk of death (134). In early mild
F with elevated left atrial pressure, diuretics, natriuretic
eptides (135), or ultrafiltration (136), administered judi-
iously to avoid systemic hypotension, baroreceptor unload-
ng, and reflexive increases in sympathetic activity or renin
elease (137), might prevent or delay reflexively increased
NES (54). A functionally important central angiotensin
I-AT1 receptor-aldosterone-reactive oxygen species excitatory
athway provides new opportunities to modulate (avoiding
blation [138]) sympathetic outflow. If present, adjunctive
herapy directed at myocardial ischemia, deconditioning, obes-
ty, uremia, or sleep apnea, that concurrently diminishes
ympathetic tone or augments tonic or reflex vagal HR
odulation could be considered (10,79,139,140).Contemporary drug management of HF has no impact
n OSA. By contrast, the sympathoinhibitory and vagotonic
ffects of CPAP during sleep (140,141) alone may be
ufficient to benefit patients with coexisting OSA. In
andomized trials lasting 1 month involving HF patients
ith OSA, nightly CPAP abolished apnea and improved
jection fraction (142) and lowered systolic BP, HR, and
SNA after waking (79,142). The latter finding is consis-
ent with elimination of an independent stimulus to sym-
athetic excitation (Fig. 2). Abolition of apneas by CPAP
ay also reduce mortality (73).
In a 3-month randomized trial involving HF patients
ith CSA, nightly CPAP suppressed apnea and reduced
octurnal urinary NE by 41%, to values in HF patients
ithout CSA. CPAP also reduced plasma NE during
akefulness by 22% (81). In a a post hoc efficacy analysis of
ata from a long-term trial involving 258 HF patients with
SA, CPAP improved significantly transplant-free survival
f those in whom apnea was suppressed below the inclusion
riterion of 15 apneic or hyponeic events/h (143).
Therapies such as beta-adrenergic antagonism and
ngiotensin-converting enzyme inhibition that diminish
oradrenergic drive, augment the vagal modulation of HR,
r both, prolong and improve the quality of life. However,
atients without evidence of residual sympathetic activita-
ion while receiving contemporary therapy may not benefit
nd might be harmed by adding sympathoinhibitory or
ympatholytic drugs (138). Without detailed clinical evalu-
tion, and hypothesis-driven trials, one cannot be certain
hat the magnitude of adrenergic activation in a particular
F patient is best managed with proven sympathomodula-
ory therapies alone, or whether there is an opportunity for
dditional intervention, directed at patient-specific sympa-
hoexcitatory mechanisms such as elevated left atrial pres-
ure, myocardial ischemia, deconditioning, or sleep apnea.
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